Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype

被引:0
作者
A. D. Blann
J. S. Mohan
D. Bareford
G. Y. H. Lip
机构
[1] University Department of Medicine,Haemostasis, Thrombosis and Vascular Biology Unit
[2] City Hospital,Department of Haematology
[3] City Hospital,undefined
来源
Journal of Thrombosis and Thrombolysis | 2008年 / 25卷
关键词
Soluble P-selectin; VEGF; D-dimers; Sickle cell disease;
D O I
暂无
中图分类号
学科分类号
摘要
Sickle cell disease (SCD) is characterised by abnormal coagulopathy and angiogenesis although their relationships in two common genotypes, homozygous (HbSS) SCD and sickle-haemoglobin C disease (HbSC), are unexplored. We measured markers of platelet activation (soluble P-selectin [sP-selectin]), fibrinolysis (D-dimer) and angiogenesis (vascular endothelial growth factor [VEGF]) in 27 HbSS patients, 37 HbSC patients and in 42 age and race matched subjects with normal haemoglobin (AA). sP-selectin (P = 0.025) and D-dimers (P < 0.001) were higher in HbSS than in HbSC but there was no difference in VEGF. In HbSC, sPselectin correlated with VEGF (P = 0.012) and D-dimers (P = 0.021). There were no significant correlations in health or in HbSS. Platelet and coagulation activation, but not angiogenic activity, is elevated in HbSS disease compared to the clinically milder HbSC genotype. The correlation between sP-selectin and VEGF in SCD and HbSC disease is consistent with the view that VEGF is released from platelets during in vivo activation.
引用
收藏
页码:185 / 189
页数:4
相关论文
共 115 条
  • [1] Francis RB(1991)Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion Blood Coagul Fibrinolysis 2 341-353
  • [2] Stuart MJ(2001)Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology Pediatr Pathol Mol Med 20 27-46
  • [3] Setty BN(2003)Hypercoagulability in sickle cell disease: a curious paradox Am J Med 115 721-728
  • [4] Ataga KI(1999)Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease J Lab Clin Med 134 352-362
  • [5] Orringer EP(2001)Thrombogenesis in sickle cell disease J Lab Clin Med 137 398-407
  • [6] Westerman MP(1998)Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion J Lab Clin Med 131 344-353
  • [7] Green D(2003)Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity Blood Coagul Fibrinolysis 14 255-259
  • [8] Gilman-Sachs A(1995)Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis Am J Pathol 146 1029-1039
  • [9] Beaman K(1999)Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells Blood 93 3824-3830
  • [10] Freels S(1999)Angiogenesis in ischemic disease Thromb Haemost 82 44-52